all the information, none of the junk | biotech • healthcare • life sciences

Verastem, Rooted at MIT, Raises $32 Million and Adds ATV and Astellas to Slate of Investors

(Page 2 of 2)

tend to resist standard chemo treatments and have been implicated as a major cause of cancer relapse and ultimately death. The fascination with cancer stem cells is so high that tiny New York-based Stemline Therapeutics, another startup working on the concept, had a standing-room-only crowd at its recent presentation at the American Society of Clinical Oncology (ASCO) conference.

Verastem has attracted an impressive slate of investors. Advanced Technology Ventures, which has offices in Waltham, MA and Palo Alto, CA, has invested in biotech startups such as Acceleron, Hydra Biosciences, and Hypnion, the latter of which it sold to Eli Lilly (NYSE: LLY) in 2007.

Astellas Venture Management, the venture arm of the Japan-based pharmaceutical giant, has backed more than 25 companies via five funds. Forrester adds that Astellas recently acquired OSI Pharmaceuticals, which “has been very active in cancer stem cells over the years. Having them involved will be fabulous.”

Founding Verastem investor Longwood is notable for its pedigree. Its partners include Sirtris co-founder and former CEO Westphal and former business development head Michelle Dipp. Westphal has been involved in founding a number of notable biotech startups, including Alnylam Pharmaceuticals (NASDAQ: ALNY) and Momenta Pharmaceuticals (NASDAQ: MNTA), but he’s best known for his Sirtris gig, which culminated in its $720 million sale to GlaxoSmithKline (NYSE: GSK) in 2008. Both Dipp and Westphal are transitioning out of GSK to focus on Longwood.

Forrester says the combination of product development and financial expertise on Verastem’s newly enhanced team of investors will be vital for moving the company forward. “These are extremely well known and sophisticated biotech investors,” he says.

Single PageCurrently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.

Comments are closed.